Get the Stockscreener App
14.92
3.24%
-0.50
Amarin Corp Adr stock is traded at $14.92, with a volume of 52,795.
It is down -3.24% in the last 24 hours and up +10.44% over the past month.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
See More
Previous Close:
$15.42
Open:
$15.28
24h Volume:
52,795
Relative Volume:
0.54
Market Cap:
$310.23M
Revenue:
$306.91M
Net Income/Loss:
$-59.11M
P/E Ratio:
-99.47
EPS:
-0.15
Net Cash Flow:
$6.35M
1W Performance:
-8.24%
1M Performance:
+10.44%
6M Performance:
-0.33%
1Y Performance:
+28.27%
1-Day Range:
$14.61
$15.45
1-Week Range:
$14.61
$16.17
52-Week Range:
$7.08
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Name
Amarin Corp Adr
Sector
Industry
Phone
353 1 6699 020
Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
14.92 | 320.62M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Oct-25-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| May-06-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-04-22 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-12-21 | Downgrade | Goldman | Neutral → Sell |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| May-05-20 | Initiated | Northland Capital | Outperform |
| Mar-31-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-31-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Mar-13-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-02-20 | Initiated | Cowen | Outperform |
| Feb-18-20 | Upgrade | Citigroup | Neutral → Buy |
| Jan-06-20 | Initiated | JP Morgan | Neutral |
| Dec-16-19 | Downgrade | Stifel | Buy → Hold |
| Nov-20-19 | Initiated | Oppenheimer | Underperform |
| Nov-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Nov-15-19 | Reiterated | SVB Leerink | Outperform |
| Oct-31-19 | Initiated | Aegis Capital | Buy |
| Oct-15-19 | Initiated | Goldman | Neutral |
| Aug-14-19 | Initiated | SVB Leerink | Outperform |
| Jul-09-19 | Reiterated | Jefferies | Buy |
| Jun-17-19 | Initiated | ROTH Capital | Buy |
| Mar-22-19 | Initiated | Stifel | Buy |
View All
Amarin Corp Adr Stock (AMRN) Latest News
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Finviz
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - Finviz
China Universal Asset Management Co. Ltd. Sells 76,302 Shares of Amarin Corporation PLC $AMRN - Defense World
Net current asset value per share of Amarin Corporation Plc Sponsored ADR – MUN:EH3 - TradingView — Track All Markets
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth - Sahm
Tops & Flops Stocks - sharewise.com
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION - GlobeNewswire Inc.
Amarin (AMRN) Unprofitable as Losses Worsen, Profit Growth Forecasts Test Bullish Turnaround Hopes - Sahm
Leerink Partners raises Amarin stock price target to $12 on strong Q3 - Investing.com
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - ADVFN
Cash from operating activities of Amarin Corporation Plc Sponsored ADR – SWB:EH3 - TradingView
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - Sahm
Amarin Corporation plc Announces $17.8 Million Registered Direct Offering of American Depositary Shares - ADVFN
Amarin stock rises after ESC Congress data on VASCEPA mechanism - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
3 Strong Buy Breakout Stocks for Explosive Returns - The Globe and Mail
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Finviz
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - Finviz
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Nasdaq
Amarin stock jumps after $25 million licensing deal with Recordati - Investing.com
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Finviz
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease - Finviz
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Finviz
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Finviz
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin urged to review strategy by major shareholders - Investing.com
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26% - Sahm
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Free float of Amarin Corporation Plc Sponsored ADR – NASDAQ:AMRN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
Amarin CorpADR (AMRN) News, Articles, Events & Latest Updates - Stocktwits
Validea Kenneth Fisher Strategy Daily Upgrade Report9/24/2022 - Nasdaq
AMRN Forecast — Price Target — Prediction for 2026 - TradingView
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan - The Globe and Mail
Generic-Drug Labeling Strategy Likely to Survive Teva Rehearing - Bloomberg.com
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
Amarin Stock Melts Down After Losing Patent Battle For Heart Drug - Investor's Business Daily
Amarin Corp Adr Stock (AMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):